Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 10 (April 1), 2005: pp. 2280-2299
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.06.104

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vandesompele, J.
Right arrow Articles by Speleman, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vandesompele, J.
Right arrow Articles by Speleman, F.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Unequivocal Delineation of Clinicogenetic Subgroups and Development of a New Model for Improved Outcome Prediction in Neuroblastoma

Jo Vandesompele, Michael Baudis, Katleen De Preter, Nadine Van Roy, Peter Ambros, Nick Bown, Christian Brinkschmidt, Holger Christiansen, Valérie Combaret, Maria Lastowska, James Nicholson, Anne O'Meara, Dominique Plantaz, Raymond Stallings, Bénédicte Brichard, Caroline Van den Broecke, Sylvia De Bie, Anne De Paepe, Geneviève Laureys, Frank Speleman

From the Center for Medical Genetics, Department of Pathology, N. Goormaghtigh Institute for Pathology, Department of Pediatric Hematology and Oncology, Ghent University Hospital, Ghent; Department of Pediatric Hematology and Oncology, Cliniques St Luc, Université Catholique de Louvain, Brussels, Belgium; Department of Pathology, Stanford University Medical Center, Stanford, CA; Medizinische Klinik und Poliklinik V der Universität Heidelberg, Heidelberg; Gemeinschaftspraxis Pathologie, Am Fuchsengraben 3, Starnberg; Universitätskinderklinik, Marburg, Germany; Children's Cancer Research Institute, St Anna Kinderspital, Vienna, Austria; Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne; Addenbrookes Hospital, Cambridge, United Kingdom; Centre d'Oncologie Génétique, Centre Léon Bérard, Lyon; Department of Pediatrics, University Hospital Center, Grenoble, France; Department of Oncology, Our Lady's Hospital for Sick Children, and National Centre for Medical Genetics, Our Lady's Hospital for Sick Children, Dublin, Ireland

Address reprint requests to Jo Vandesompele, Center for Medical Genetics Ghent (CMGG), Ghent University Hospital, MRB, De Pintelaan 185, B-9000 Ghent, Belgium; e-mail: Joke.Vandesompele{at}UGent.be

PURPOSE: Neuroblastoma is a genetically heterogeneous pediatric tumor with a remarkably variable clinical behavior ranging from widely disseminated disease to spontaneous regression. In this study, we aimed for comprehensive genetic subgroup discovery and assessment of independent prognostic markers based on genome-wide aberrations detected by comparative genomic hybridization (CGH).

MATERIALS AND METHODS: Published CGH data from 231 primary untreated neuroblastomas were converted to a digitized format suitable for global data mining, subgroup discovery, and multivariate survival analyses.

RESULTS: In contrast to previous reports, which included only a few genetic parameters, we present here for the first time a strategy that allows unbiased evaluation of all genetic imbalances detected by CGH. The presented approach firmly established the existence of three different clinicogenetic subgroups and indicated that chromosome 17 status and tumor stage were the only independent significant predictors for patient outcome. Important new findings were: (1) a normal chromosome 17 status as a delineator of a subgroup of presumed favorable-stage tumors with highly increased risk; (2) the recognition of a survivor signature conferring 100% 5-year survival for stage 1, 2, and 4S tumors presenting with whole chromosome 17 gain; and (3) the identification of 3p deletion as a hallmark of older age at diagnosis.

CONCLUSION: We propose a new regression model for improved patient outcome prediction, incorporating tumor stage, chromosome 17, and amplification/deletion status. These findings may prove highly valuable with respect to more reliable risk assessment, evaluation of clinical results, and optimization of current treatment protocols.

Supported by BOF-grant 011F1200 and 011B4300, GOA-grant 12051203, FWO-grant G.0028.00 and VEO-grant 011V1302. Katleen De Preter is an aspirant with the Fund for Scientific Research Flanders (FWO-Vlaanderen). Nadine Van Roy is a post-doctoral researcher with the FWO. Jo Vandesompele is supported by a post-doctoral grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT).

Presented in part at the Advances in Neuroblastoma Research Meeting, Paris, France, June 17-19, 2002, and at the 8th European Workshop on Cytogenetics and Molecular Genetics of Human Solid Tumours, Barcelona, Spain, September 12-15, 2002.

This text presents research results of the Belgian program of Interuniversity Poles of Attraction initiated by the Belgian State, Prime Minister's Office, Science Policy Programming.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
BioinformaticsHome page
J. Liu, N. Bandyopadhyay, S. Ranka, M. Baudis, and T. Kahveci
Inferring progression models for CGH data
Bioinformatics, September 1, 2009; 25(17): 2208 - 2215.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. De Preter, S. De Brouwer, T. Van Maerken, F. Pattyn, A. Schramm, A. Eggert, J. Vandesompele, and F. Speleman
Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds
Clin. Cancer Res., June 1, 2009; 15(11): 3690 - 3696.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
I. Janoueix-Lerosey, G. Schleiermacher, E. Michels, V. Mosseri, A. Ribeiro, D. Lequin, J. Vermeulen, J. Couturier, M. Peuchmaur, A. Valent, et al.
Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma
J. Clin. Oncol., March 1, 2009; 27(7): 1026 - 1033.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. H. Schulte, S. Lim, A. Schramm, N. Friedrichs, J. Koster, R. Versteeg, I. Ora, K. Pajtler, L. Klein-Hitpass, S. Kuhfittig-Kulle, et al.
Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy
Cancer Res., March 1, 2009; 69(5): 2065 - 2071.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. L. Cohn, A. D.J. Pearson, W. B. London, T. Monclair, P. F. Ambros, G. M. Brodeur, A. Faldum, B. Hero, T. Iehara, D. Machin, et al.
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
J. Clin. Oncol., January 10, 2009; 27(2): 289 - 297.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Oberthuer, L. Kaderali, Y. Kahlert, B. Hero, F. Westermann, F. Berthold, B. Brors, R. Eils, and M. Fischer
Subclassification and Individual Survival Time Prediction from Gene Expression Data of Neuroblastoma Patients by Using CASPAR
Clin. Cancer Res., October 15, 2008; 14(20): 6590 - 6601.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
J. Liu, S. Ranka, and T. Kahveci
Classification and feature selection algorithms for multi-class CGH data
Bioinformatics, July 1, 2008; 24(13): i86 - i95.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
J. Liu, S. Ranka, and T. Kahveci
Markers improve clustering of CGH data
Bioinformatics, February 15, 2007; 23(4): 450 - 457.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Chen and R. L. Stallings
Differential Patterns of MicroRNA Expression in Neuroblastoma Are Correlated with Prognosis, Differentiation, and Apoptosis
Cancer Res., February 1, 2007; 67(3): 976 - 983.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Van Maerken, F. Speleman, J. Vermeulen, I. Lambertz, S. De Clercq, E. De Smet, N. Yigit, V. Coppens, J. Philippe, A. De Paepe, et al.
Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
Cancer Res., October 1, 2006; 66(19): 9646 - 9655.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
J. Liu, J. Mohammed, J. Carter, S. Ranka, T. Kahveci, and M. Baudis
Distance-based clustering of CGH data
Bioinformatics, August 15, 2006; 22(16): 1971 - 1978.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Q. Wang, S. Diskin, E. Rappaport, E. Attiyeh, Y. Mosse, D. Shue, E. Seiser, J. Jagannathan, S. Shusterman, M. Bansal, et al.
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number.
Cancer Res., June 15, 2006; 66(12): 6050 - 6062.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. L. Stallings, P. Nair, J. M. Maris, D. Catchpoole, M. McDermott, A. O'Meara, and F. Breatnach
High-Resolution Analysis of Chromosomal Breakpoints and Genomic Instability Identifies PTPRD as a Candidate Tumor Suppressor Gene in Neuroblastoma.
Cancer Res., April 1, 2006; 66(7): 3673 - 3680.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online